MARKET

AXSM

AXSM

Axsome
NASDAQ

Real-time Quotes | Nasdaq Last Sale

51.71
-1.73
-3.24%
Opening 12:12 04/19 EDT
OPEN
53.48
PREV CLOSE
53.44
HIGH
54.37
LOW
51.41
VOLUME
87.76K
TURNOVER
--
52 WEEK HIGH
109.53
52 WEEK LOW
51.00
MARKET CAP
1.93B
P/E (TTM)
-18.6969
1D
5D
1M
3M
1Y
5Y
Global Major Depressive Disorder (MDD) Drug Market Report 2021: Therapeutics Market Will Grow to $7.9B by 2029
Dublin, April 19, Apr 19, 2021 (GLOBE NEWSWIRE via COMTEX) -- Dublin, April 19, 2021 (GLOBE NEWSWIRE) -- The "Major Depressive Disorder - Global Drug...
GlobeNewswire · 4h ago
The Daily Biotech Pulse: Novavax CFO Departs, Zai Lab Inks Cancer Drug Collaboration, FDA Nod For Gilead
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 13)
Benzinga · 5d ago
The Daily Biotech Pulse: Leadership Transition At Amarin, Vaccine Setback For J&J, FDA Nod For Label Expansion of Roche's Asthma Drug
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 12)
Benzinga · 6d ago
The Daily Biotech Pulse: Negative Regulatory Tidings For Provention Bio, Celcuity Soars On In-licensing Deal, 2 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 8)
Benzinga · 04/09 11:26
Major Depressive Disorder - Global Drug Forecast and Market Analysis to 2029
New York, April 09, Apr 09, 2021 (GLOBE NEWSWIRE via COMTEX) -- New York, April 09, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the...
GlobeNewswire · 04/09 07:45
Why Is Axsome (AXSM) Down 19.9% Since Last Earnings Report?
Axsome (AXSM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks · 03/31 16:30
Read This Before Selling Axsome Therapeutics, Inc. (NASDAQ:AXSM) Shares
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. The...
Simply Wall St. · 03/30 06:05
Complex Regional Pain Syndrome Treatment Market Size, Share Report 2021 Shipments, Price, Revenue and Gross Profit till 2026 With Impact of COVID-19
The Express Wire · 03/22 06:06
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of AXSM. Analyze the recent business situations of Axsome through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 14 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average AXSM stock price target is 143.85 with a high estimate of 210.00 and a low estimate of 62.00.
EPS
Institutional Holdings
Institutions: 256
Institutional Holdings: 28.05M
% Owned: 74.98%
Shares Outstanding: 37.41M
TypeInstitutionsShares
Increased
67
1.36M
New
23
910.69K
Decreased
58
1.57M
Sold Out
17
451.71K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-1.85%
Pharmaceuticals & Medical Research
-0.38%
Key Executives
Chairman/President/Chief Executive Officer/Founder/Director
Herriot Tabuteau
Chief Financial Officer
Nick Pizzie
Chief Operating Officer
Mark Jacobson
Finance Director/Chief Accounting Officer
Joseph Debrah-Affu
Senior Vice President
Amanda Jones
Senior Vice President
Cedric O'Gorman
Other
David Marek
Lead Director/Independent Director
Roger Jeffs
Independent Director
Mark Coleman
Independent Director
Mark Saad
No Data
About AXSM
Axsome Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing therapies for the management of central nervous system (CNS) disorders, including pain. It operates in the business of developing novel therapies for the management of CNS disorders segment. Its product candidate, AXS-02 (disodium zoledronate tetrahydrate), is an oral, targeted, non opioid therapeutic for chronic pain. It is developing AXS 02 for the treatment of pain in over three conditions, such as complex regional pain syndrome (CRPS); knee osteoarthritis (OA) associated with bone marrow lesions (BMLs), and chronic low back pain (CLBP), associated with type I, or mixed type I and type II Modic changes (MCs). Its product candidate, AXS 05, is a fixed dose combination of dextromethorphan (DM) and bupropion. It is developing AXS 05 for the treatment of over two conditions, such as treatment resistant depression (TRD), and agitation in patients with Alzheimer's disease (AD).

Webull offers kinds of Axsome Therapeutics Inc stock information, including NASDAQ:AXSM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AXSM stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AXSM stock methods without spending real money on the virtual paper trading platform.